Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05864144 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

StatusCompleted
PhasePhase 1/2
Started2023-05-31
View on ClinicalTrials.gov ↗
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

Amendment history 3 changes detected by DataLookout

2026-09-03
Trial completed
2026-09-03
Primary endpoint(s) modified
WasAdverse Events - Part A & B, Determine the Recommended Phase 2 dose or maximum tolerated dose - Part A & B, Objective Response Rate (ORR) - Part C
NowAdverse Events - Part A & B, Determine the Recommended Phase 2 dose or maximum tolerated dose - Part A & B, Objective Response Rate (ORR) - Part C. Part C was never initiated.
2026-09-03
Primary completion confirmed: June 2026 (last estimated June 2027)
Trial Details
NCT Number NCT05864144
Lead Sponsor Sensei Biotherapeutics, Inc.
Collaborators: Regeneron Pharmaceuticals
Conditions Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer +14 more
Enrollment 98 participants
Start Date 2023-05-31
Primary Completion 2026-06-02 (estimated)
Study Completion 2026-06-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-02